Rhythm specializes in treatments for metabolic conditions and severe obesity.

AstraZeneca may not need a major acquisition to sustain growth beyond 2030—but the British pharma is reportedly not stopping ...

By Sabrina Valle, Milana Vinn and Amy-Jo Crowley Nov 4 (Reuters) - AstraZeneca made an offer of about $10 billion to acquire ...

Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual ...

Strategic partnerships and accelerating trial readouts position the company to replace revenue lost to patent cliffs.

AstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not ...

AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears ...

AstraZeneca PLC (LSE:AZN, NYSE:AZN), the Anglo-Swedish drugmaker, saw three brokers raise their price targets after its third ...

AstraZeneca is teaming up with Oracle to refine clinical research, in the latest artificial-intelligence partnership in the pharmaceutical industry.

Rhythm (RYTM) stock jumped 28% to $110.68 after reports AstraZeneca offered up to $134 a share, about $10 billion, to buy the ...

AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to ...